Antisense oligonucleotides in cutaneous therapy.
Antisense oligonucleotides have been the subject of intense interest as research tools to elucidate the functions of gene products and as therapeutic agents. Initially, their mode of action was poorly understood and the biological effects of oligonucleotides were often misinterpreted. However, research into these gene-based inhibitors of cellular action recently has succeeded in realising their exciting potential, particularly as novel therapeutic agents. An emerging application of this technology is in cutaneous therapy. The demand for more effective dermatological drugs will ensure further development of antisense strategies in skin, with key issues being drug delivery, therapeutic target selection, and clinical applicability.
Wraight
C J
CJ
Centre for Hormone Research, Murdoch Childrens Research Institute, Flemington Road, Parkville, Victoria 3052, Australia. wraight@cryptic.rch.unimelb.edu.au
White
P J
PJ
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D016503:Drug Delivery Systems; D015195:Drug Design; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D015394:Molecular Structure; D016376:Oligonucleotides, Antisense / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000633:toxicity; D012333:RNA, Messenger / Q000378:metabolism; D012871:Skin Diseases / Q000188:drug therapy* / Q000235:genetics / Q000821:virology; D012878:Skin Neoplasms / Q000188:drug therapy; D013873:Thionucleotides / Q000737:chemistry / Q000627:therapeutic use
D000970:Antineoplastic Agents; D000998:Antiviral Agents; D003879:Dermatologic Agents; D016376:Oligonucleotides, Antisense; D012333:RNA, Messenger; D013873:Thionucleotides; C091346:fomivirsen